CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Dr. Musunuru and Dr. Ahrens-Nicklas holding KJ post infusion Senior Correspondent Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments ...

In the late 2010s eight macaque monkeys were born at a laboratory in Shanghai. At first they seemed much like the other infants in the colony, but differences soon became obvious. They were much more ...

The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders. A gene-editing ...

While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...

The daily burden for those living with type 1 diabetes is constant, and Breakthrough T1D remains focused on accelerating the path to cures for the disease,” said Nicholas Mamrak, Ph.D., scientist at ...

In July, we reported that lecanemab (Leqembi) won full FDA approval to treat Alzheimer's disease. In this article, we look beyond anti-amyloid agents like lecanemab to see what other targets are being ...